Laermans, Jorien http://orcid.org/0000-0002-6695-6019
Van Remoortel, Hans
Scheers, Hans
Avau, Bert
Georgsen, Jørgen
Nahirniak, Susan
Shehata, Nadine
Stanworth, Simon J.
De Buck, Emmy
Compernolle, Veerle
Vandekerckhove, Philippe
Funding for this research was provided by:
European Blood Alliance (2021-01)
Foundation for Scientific Research of the Belgian Red Cross
Article History
Accepted: 24 May 2023
First Online: 26 June 2023
Declarations
:
: This work is supported in part by a grant from the European Blood Alliance (EBA) (grant 2021-01) and in part by structural support from the Foundation for Scientific Research of the Belgian Red Cross. The sponsors had no part in the design of this protocol. The contents of this document do not necessarily reflect the views and policies of the EBA, nor does mentioning of trade names or commercial products constitute endorsement or recommendation of use.
: Relevant financial conflicts of interest directly related to this review: All authors declared not having any relevant direct financial conflict of interest. Relevant financial conflicts of interest not directly related to this review: JL, HVR, HS, BA, EDB, VC and PV are employees of Belgian Red Cross–Flanders, which is responsible for supplying adequate quantities of safe blood products to hospitals in Flanders and Brussels on a continuous basis and is funded by the Ministry of Social Affairs. Belgian Red Cross–Flanders received a grant from the European Blood Alliance to conduct this review. SS is an employee of NHS Blood and Transplant, which is the blood service supplier for England and manufactures platelets, and Chair International Collaboration for Transfusion Medicine Guidelines (ICTMG). SS reports research grant funding for trials using platelets and tranexamic acid. JG and SN declared not having any other financial conflicts of interest. NS received personal fees from the Canadian Blood Services for the International Collaboration for Transfusion Medicine Guidelines (ICTMG). SS received a grant award to conduct trials on use of platelets and tranexamic acid in patients with haematological cancer and a grant award to conduct trials on using platelets in neonates. Relevant intellectual conflicts of interest: JL, HVR, HS, BA, JG, EDB, VC and PV declared not having any intellectual conflict of interest. NS, SN and SS declare involvement in the ICTMG platelet guideline (SS is the chair, SN is the co-chair).
: All (secondary) data generated or analysed during this study are included in this published article and its Online Resources.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: JL: Conceptualization, Investigation, Formal analysis, Writing—Original draft, Visualization. HVR: Conceptualization, Investigation, Formal analysis, Writing—Review & Editing, Visualization, Supervision, Project administration, Funding acquisition. HS: Investigation, Formal analysis, Writing—Review & Editing, Visualization. BA: Conceptualization, Investigation, Writing—Review & Editing, Supervision, Project administration, Funding acquisition. JG: Validation, Writing—Review & Editing. SN: Validation, Writing—Review & Editing. NS: Validation, Writing—Review & Editing. SS: Validation, Writing—Review & Editing. EDB: Conceptualization, Writing—Review & Editing, Supervision. VC: Conceptualization, Writing—Review & Editing, Supervision. PV: Conceptualization, Resources, Writing—Review & Editing, Supervision.